Sep 2026· Advancement of science· 0 citations· 43 references
Medicine
TL;DR
Smart, programmable membrane-engineered nanosponges (ACNPs) displaying high-density ACE2 and encapsulating the viral entry inhibitor camostat enforces sequential recognition and endocytosis blockade, offering a deployable, non-invasive, universal strategy for early intervention against pan ACE2-dependent coronaviruses and future "X viruses".
Abstract
ABSTRACT Coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), severe acute respiratory syndrome coronavirus (SARS‐CoV), and human coronavirus NL63 (HCoV‐NL63), infect host cells through spike (S) protein binding to angiotensin‐converting enzyme 2 (ACE2). Although soluble ACE2 can neutralize virions, its efficacy is limited by viral load and binding affinity. Herein, we engineered smart, programmable membrane‐engineered nanosponges (ACNPs) displaying high‐density ACE2 and encapsulating the viral entry inhibitor camostat. Combining customized ACE2 receptors with camostat enforces sequential recognition and endocytosis blockade: viruses are captured through S protein–ACE2 binding, followed by suppression of S protein cleavage to inhibit viral endocytosis and achieve ultra‐early blockade at the infection source. ACNPs exhibit an IC50 that is 22‐fold lower than that of ACE2‐only nanosponges and prevent more than 99% of viral entry. After intratracheal nebulization, ACNPs persist in the lungs for over 72 h, achieving over 92% viral clearance and 80%–100% survival. ACNPs also inhibit authentic HCoV‐NL63 infection, offering a deployable, non‐invasive, universal strategy for early intervention against pan ACE2‐dependent coronaviruses and future “X viruses”.
A comprehensive analysis of the molecular mechanisms underlying EV-virus interactions highlighting the therapeutic and diagnostic potential of EVs in tackling COVID-19 and future viral pandemics is provided.
S. Dutta, Sauradeep Dutta, Yohan Han et al.· Current Issues in Molecular...· 0 citations
SBP10 and SBP16 function as dual targeting engineered binding proteins that inhibit viral entry while attenuating complement-mediated inflammation, highlighting a promising therapeutic strategy for controlling SARS-CoV-2 infection and its associated immune dysregulation.
Fan Pu, Yi-Wan Guo, Xinni Pan et al.· Antiviral Research· 0 citations
The findings discussed in this review underscore the promise of eco-friendly nanotechnology as a sustainable and effective platform for developing next-generation antiviral therapies against dengue virus.
D. M. Kumar, R. Bharath, P. Venkataraman et al.· Viruses· 0 citations
This review focuses on selected, representative antiviral inhibitors directed against viral proteins of human coronaviruses, offering an integrated overview of current antiviral candidates and illustrates the central role of viral proteins as points of intervention.
Álvaro de la Cruz-Potenciano, Miguel Maldonado, M. Camarasa et al.· ChemMedChem· 0 citations
A genome engineering technology is used to change a single amino acid in the viruses’ main protease enzyme to match that of circulating Omicron isolates to demonstrate antiviral efficacy of approved drugs and uncover mutants with reduced drug sensitivity.
ABSTRACT Neurotropic coronaviruses can invade the central nervous system (CNS) and cause severe neurological disease, but the mechanisms underlying virus-induced neuroinflammation remain incompletely understood. Here, we report that infection with porcine hemagglutinating encephalomyelitis virus (PHEV), a neurotropic b...
A new machine-learning framework aims to improve the success rate of computational protein design while moving away from results that reproduce sequences found in nature.